Fos-related antigen 1 (Fra-1) is a Fos family member overexpressed in several types of human cancers. Here, we report that Fra-1 is highly expressed in the muscleinvasive form of the carcinoma of the bladder (80%) and to a lesser extent in superficial bladder cancer (42%). We demonstrate that in this type of cancer Fra-1 is regulated via a C-terminal instability signal and C-terminal phosphorylation. We show that manipulation of Fra-1 expression levels in bladder cancer cell lines affects cell morphology, motility and proliferation. The gene coding for AXL tyrosine kinase is directly upregulated by Fra-1 in bladder cancer and in other cell lines. Importantly, our data demonstrate that AXL mediates the effect of Fra-1 on tumour cell motility but not on cell proliferation. We suggest that AXL may represent an attractive therapeutic target in cancers expressing high Fra-1 levels.
Introduction
Prototypical AP-1 complexes represent heterodimers between basic region-leucine zipper transcription factors of Jun (c-Jun, JunB and JunD) and Fos (c-Fos, FosB, Fra-1 (Fos-related antigen 1) and Fra-2) families. Jun proteins exist also as homodimers and ATF/Jun heterodimers, and members of both subfamilies interact with other more distantly related transcription factors, such as Maf, NFkB, GATA and so on (Shaulian and Karin, 2002; Eferl and Wagner, 2003) . AP-1 family members are activated by various signalling pathways that regulate basic aspects of cell physiology, including proliferation, differentiation and apoptosis. Activated Jun/Fos heterodimers interact with target cis-elements, TRE (TPA-responsive elements, TGA(G/C)TCA), located in transcriptional promoters of a number of cancerrelated genes, implicating AP-1 in cancer biology (Ozanne et al., 2006) . Among the four Fos family members, Fra-1 (encoded by the fosl1 gene) is likely to be the most frequently expressed in different forms of human cancer (Milde-Langosch, 2005; Young and Colburn, 2006) .
Elevated expression of Fra-1 in these neoplasms can be explained by the fact that it is strongly activated by the oncogenic RAS-RAF-MEK-ERK-RSK pathway, most often hyperactivated in different cancer types. There are at least two levels of Fra-1 activation by this pathway: transcriptional, via an AP-1-dependent intronic enhancer in fosl1, and post-translational, through phosphorylation of two C-terminal serine residues, Ser-252 and Ser-265 (Bergers et al., 1995; Casalino et al., 2003; Murphy et al., 2004; Verde et al., 2007) . Phosphorylation of these serines by RSK and ERK protein kinases, respectively, results in inactivation of a C-terminal instability domain, which when non-phosphorylated, promotes ubiquitin-independent proteasomal degradation of Fra-1 (Basbous et al., 2007) . Activation of Fra-1 by the RAS pathway seems to have a fundamental role as a common mechanism of tumourigenesis. Kakumoto et al. (2006) addressed the difference in susceptibility to oncogenic transformation between human and rodent fibroblasts. In contrast to rat cells, signalling downstream of ERK is suppressed in human fibroblasts expressing mutant RAS, and this suppression uncouples the RAS pathway from Fra-1 activation. The transformed phenotype was rescued by exogenous Fra-1, suggesting that a defect in Fra-1 protein accumulation renders human cells insensitive to oncogenic transformation (Kakumoto et al., 2006) .
Experimental modulation of Fra-1 levels in cancer cell lines has highlighted its role in a number of pathways controlling the essential features of malignancy. Fra-1 directly regulates transcription of CCND1 and is required for mouse alveolar epithelial cells to progress through G1 phase of the cell cycle (Burch et al., 2004) . Moreover, the growth-promoting effect of p73 in fibroblasts is mediated by Fra-1/c-Jun-dependent activation of CCND1, suggesting the Fra-1-cyclin D1 regulatory link is conserved and has a widespread role (Vikhanskaya et al., 2007) . A role for Fra-1 in cell cycle regulation is not restricted to the G0-G1 or G1-S phase transition. In cycling thyroid carcinoma cells, Fra-1 is recruited to several TRE elements in CCNA2 gene promoter specifically during G2 phase of the cell cycle. In this cell model, transcriptional activation of cyclin A by Fra-1 is critical for the G2-M transition and mitosis; Fra-1 depletion leads to mitotic catastrophe . Obviously, as mitotic catastrophe results in cell death, these data indicate that Fra-1 may have an antiapoptotic function. Likewise, Fra-1 protected colon carcinoma cells with hyperactivated MAPK signalling from anoikis .
Several lines of evidence suggest that Fra-1 is implicated in regulating tumour cell motility and invasion. A number of direct or indirect transcriptional Fra-1 targets are genes that facilitate degradation of extracellular matrix (MMP-1, MMP9 and components of uPA system) (Kustikova et al., 1998; Andersen et al., 2002; Belguise et al., 2005) , and affect cell adhesion or pro-migratory signalling (CD44, c-met and VEGF) (Ramos-Nino et al., 2003) . In a recent study, Fra-1 was shown to be in part responsible for the promigratory and pro-invasive gene expression programme induced via the RAS-ERK-RSK axis, and it regulates expression of nearly a quarter of all RSK target genes (Doehn et al., 2009) . Similarly, in MCF-10A cells, Fra-1 was required for increased motility and epithelial mesenchymal transition (EMT) induced by ERK2. The EMT programme was executed by embryonic transcription factors ZEB1 and ZEB2, which acted downstream of Fra-1 (Shin et al., 2010) . In breast and colon carcinoma-or in glioblastoma-derived cell lines, Fra-1 knockdown resulted in prominent alterations in cell morphology and it altered the configuration and the distribution of actin filaments Belguise et al., 2005; Pollock et al, 2005; Debinski and Gibo, 2005) . Fra-1 counteracted stress fibre formation by either reducing RhoA activity or interfering with this pathway downstream of Rho (Pollock et al., 2005) , resulting in increased cell motility and decreased adhesion.
Here, we address the role for Fra-1 in bladder cancer, a form of cancer in which Fra-1 involvement has not yet been investigated. Bladder cancer is the fifth most common cancer worldwide and patients with invasive disease have poor prognosis, with a 50% 5-year survival. The absolute majority of bladder tumours are classified as transitional cell carcinoma (TCC), which is divided into two types, superficial (75%) and muscle-invasive (25%) (Mitra and Cote, 2009) . In many cases, muscleinvasive TCCs manifest metastatic features that represent the major cause of patient death. Our data demonstrate that Fra-1 is broadly expressed in this form of malignancy. Moreover, we report on the identification of a novel potentially 'druggable' Fra-1 target, the receptor tyrosine kinase AXL, which acts downstream of Fra-1 and is required for tumour cell motility.
Results
Fra-1 is broadly expressed in bladder tumours and in bladder cancer cell lines Although RAS pathway deregulation is involved in the aetiology of bladder cancer, there are no studies on the expression of Fra-1 in this type of malignancy. Oncomine database search has shown that Fra-1 was upregulated by a factor of 2 or more in 5 out of 14 available bladder cancer cDNA microarrays. Therefore, we performed the IHC analysis of Fra-1 expression in 156 specimens of TCC of the bladder. The majority of cancer specimens (67%) contained a proportion (>5%) of tumour cells with nuclear Fra-1. The main staining pattern was nuclear distribution that tended to be more marked in less differentiated or clearly invasive zones and in large and often pleomorphic nuclei ( Figure 1a) . In a lesser proportion of cases (12%), we detected cytoplasmic Fra-1 localisation. Although no nuclear Fra-1 was detected in non-malignant bladder urothelium, cytoplasmic Fra-1 was present in a fraction of samples. Nuclear Fra-1 significantly correlated with tumour stage (two-tailed Fischer's exact test Po0.001): higher (T 2 þ T 3 þ T 4 ) and lower (T a þ T 1 ) stage tumours were scored as Fra-1-positive in 80% and 42% of cases, respectively ( Figure 1a ). Cytoplasmic Fra-1 was rare in higher (detected in 5 out of 104 specimens only), but more frequent (27%) in low-stage tumours. We observed a trend towards elevated expression of nuclear Fra-1 in higher-grade samples, but this correlation was statistically insignificant (data not shown). Overall, we observed frequent Fra-1 expression in TCC of the bladder, which was significantly higher in T 2 þ T 3 þ T 4 than in T a þ T 1 tumours. T a þ T 1 represents a superficial form of TCC, which does not progress towards malignancy and is not life threatening. T 2 þ T 3 þ T 4 stages are the muscle-invasive form, which is a deadly disease with 50% 5-year survival rate. Thus, our data show that nuclear Fra-1 is present in cells of more advanced tumours, and Fra-1 immunopositivity negatively correlates with the survival of cancer patients. Next, we assessed Fra-1 expression in six bladder cancer cell lines derived from muscle-invasive (J82, RT112, T24, HT1376 and UMUC-3) or papillary (RT4) carcinoma. Fra-1 expression inversely correlated with E-cadherin status, in agreement with the ability of E-cadherin to suppress Fra-1 expression (Andersen et al., 2005) and with the proposed role for Fra-1 in EMT (Shin et al., 2010) (Figure 1b) . In bladder cancer cell lines, Fra-1 was detected as a smear or as several closely migrating bands in B35-45 kDa range, suggesting that the protein is phosphorylated at several sites. Indeed, in vitro dephosphorylation reaction using calf intestinal phosphatase eliminated all slowly migrating species (Figure 1c) .
Fra-1 expression is controlled by C-terminal instability signal and C-terminal phosphorylation MEK-dependent phosphorylation of Ser-252 and Ser-265 is known to stabilise Fra-1 in colon cancer cells, and C-terminal 40-amino-acid residues contain an instability signal (Basbous et al., 2007) . We addressed the relevance of these mechanisms to Fra-1 regulation in bladder cancer cell lines. To this end, we generated two series of vectors expressing Fra-1 deletion or aminoacid substitution mutants and analysed the expression levels of these Fra-1 derivatives in bladder cancer cells (Figure 2a) . Deletion of as little as three C-terminal amino acids, LAL, strongly increased Fra-1 protein level in J82 or RT4 cell lines that are positive or negative for Fra-1, respectively (Figure 2b ). Using pulse chase experiments with metabolically labelled J82 cells expressing Fra-1 wild-type or Fra-1D3, we observed that C-terminal deletion significantly stabilised the protein (data not shown). Further deletions did not enhance the stabilisation (Figure 2b ). In agreement with previously published data, phosphomimetic mutations at Ser-252 and Ser-265 enhanced Fra-1 expression in transiently transfected bladder cancer cell lines or in stable transfectants (Figure 2c and see Figure 4a ). As we expected, mutating those serines to alanines reduced Fra-1 expression levels in transient transfections (data not shown) and in stable transfectants (see Figure 4a) . However, mutating Thr-240 or four threonine residues located more distantly from the C-teminus (Thr-219, -223, -227 and -230) to aspartic acids produced only Fra-1 controls motility of bladder cancer cells AE Sayan et al minor effects on Fra-1 expression levels ( Figure 2c ). On the other hand, phosphomimetic mutations introduced at sites adjacent to Ser-252 and Ser-265 (Ser-251 and Thr-267) stabilised Fra-1. Thus, phosphorylation of Fra-1 at residues near the C-terminus stabilises the protein, and phosphorylation of Ser-265 has the strongest effect.
We addressed a question as to whether is Fra-1 phosphorylated at its C-terminus in cell lines and in tumour tissues. Using a phospho-specific Ser-265 antibody, we detected U0126-sensitive Fra-1 C-terminal phosphorylation in asynchronously growing J82 cells expressing wild-type Fra-1. Fra-1D3 produced in J82 or RT112 cells was immunoreactive to the P-Ser-265 antibody (Figure3a and data not shown). Although the level of phospho-ERK was high in RT4 cells (McHugh et al., 2009) , this cell line was not competent of expressing high levels of wild-type Fra-1, and stabilised Fra-1D3 mutant was not phosphorylated at Ser-265. This was in sharp contrast with J82 ( Figure 3a ) and RT112 (data not shown) cell lines, and suggested that activated RAS pathway may be suppressed downstream of activated ERK, as it has been observed in immortalised human fibroblasts expressing oncogenic H-RAS (Kakumoto et al., 2006) . To analyse Fra-1 C-terminal phosphorylation in tumour tissues, we selected 10 Fra-1-positive samples and re-assessed them using P-Ser-265 antibody and a conventional anti-Fra-1 antibody in parallel sections. In all samples, we found Fra-1 was phosphorylated at Ser-265 ( Figure 3b ).
Accumulation of Fra-1 in bladder tumour cells alters cell morphology, motility and proliferation
After having demonstrated frequent expression of stabilised forms of Fra-1 in bladder cancer, we aimed to Figure 4 Stabilised forms of Fra-1, but not a stable leucine zipper-deficient Fra-1 mutant, alter cell morphology, motility and cell proliferation. (a) RT112 cell populations stably transfected with indicated mutants express different Fra-1 levels. In all, 20 mg of proteins from stable cell lines was analysed by western blotting for exogenous Fra-1 expression. An a-tubulin antibody was used to control for equal loading. (b) Stabilised forms of Fra-1 alter cell morphology. Merged confocal microscopic images of control RT112 cells or RT112 cells expressing indicated Fra-1 mutants. DAPI, blue; Fra-1, red; filamentous actin, green. (c) Effect of Fra-1 mutants on migration of RT112 cells. RT112 cells stably expressing Fra-1 derivatives were seeded in Transwell inserts, and cell motility was analysed as described in Materials and methods. The experiment was performed three times with similar results; results of one experiment are shown. (d) Fra-1D3, but not Fra-1LZ, stimulates migration of HT1376 cells in Transwell assay. Populations of HT1376 cells stably expressing Fra-1D3, Fra-1LZ or control HT1376 cells transfected with the wild-type pIRESpuro 2 vector were seeded into Transwell inserts at a concentration of 2 Â 10 5 cells per well. Cells were allowed to migrate towards serum gradient for 4 h and analysed in three independent triplicate experiments with similar results. Data (mean±s.d.) show the results of one triplicate experiment. Expression of Fra-1D3 and Fra-1LZ was analysed in western blotting. (e) Wild-type Fra-1, Fra-1DD and Fra-1D3 activate cell proliferation. Cells were seeded in triplicate in 24-well plates and allowed to proliferate for 24, 48, 72 and 96 h. Cells were stained by DAPI and counted using Image-J software. Fra-1 controls motility of bladder cancer cells AE Sayan et al analyse the functional consequences of Fra-1 accumulation in bladder cancer cells. To this end, we stably transfected RT112 cells with the pIRESpuro2 vector expressing stabilised forms of Fra-1 (Fra-1D3, Fra-1SD and Fra-1DD). As negative control, a stable Fra-1LZ mutant defective in Jun binding or empty pIRESpuro2 vector was used (Figure 2a ). In addition, to analyse the effects of moderate or low Fra-1 levels, we employed wild-type Fra-1 or Fra-1 with destabilising Ser/Ala C-terminal substitutions (Fra-1AA). Expression level of Fra-1 derivatives in stably transfected cell population was consistent with the results of transient transfections (Figure 4a ). Except for the LZ mutant, which was detected in both the nuclei and the cytoplasm, all Fra-1 derivatives exhibited merely nuclear localisation. Interestingly, we observed changes in cell morphology in cells expressing stabilised Fra-1 mutants with the native LZ domain. In these cell lines, the characteristically epithelial groups of RT112 cells became less compact, exhibiting a disrupted circumferential actin filament network and lamellipodia-like protrusions ( Figure 4b ). In contrast, cells expressing the unstable Fra-1AA mutant or high levels of Fra-1LZ mutant were morphologically identical to parental cells or cells transfected with pIRESpuro2. Though the observed alterations were reminiscent of EMT, all cell populations remained E-cadherin-positive, and no strong alterations in the expression of other EMT markers were observed (data not shown). In line with the changes in their phenotype, cells expressing stable Fra-1 mutants exhibited enhanced motility in Transwell migration assays ( Figure 4c ). To generalise our findings, we performed analogous experiments in another Fra-1-negative cell line, HT1376. Pools of HT1376 cells expressing Fra-1D3 or Fra-1LZ were generated and analysed in Transwell assays. Fra-1D3-expressing HT1376 cells were 6-or 13-fold more motile than parental or Fra-1LZ-expressing cells, confirming a pro-migratory function of Fra-1 in bladder cancer cells (Figure 4d ). In addition, we found that Fra-1 strongly enhanced the proliferation rate of RT112 ( Figure 4e ) and HT1376 (data not shown) cells. Proliferation of RT112 cells expressing Fra-1AA mutant was similar to the control cell population. The important role for Fra-1 in control of cell migration and proliferation in bladder cancer cell lines was confirmed by a knockdown approach. Small interference RNAmediated Fra-1 depletion in bladder cancer cell lines with high levels of endogenous Fra-1 strongly reduced proliferation (analysed in J82 cells) and migration of J82 and UMUC-3 cells in Transwell motility assay (see also Figure 8b ).
AXL receptor tyrosine kinase is a universal Fra-1 target We performed a search for Fra-1 transcriptional targets to identify molecular pathways affected by Fra-1 in bladder cancer cells. Given that C-terminal phosphorylation was detected in the majority of bladder tumours and bladder cancer cell lines, we compared gene expression patterns in control RT112 and RT112/Fra-1DD cells. By using a qPCR-based cDNA microarray technology, we identified 76 genes up-or downregulated by Fra-1 by a factor of 2 or more (data not shown). One of the genes most strongly upregulated in cells expressing Fra-1DD was AXL, a receptor tyrosine kinase superfamily member (Figure 5a ). This protein was selected for further studies for several reasons. First, AXL is an oncogene implicated in cell motility, adhesion and cell growth (Linger et al., 2008) , suggesting that it may function in the same pathways as Fra-1. Second, we observed a perfect correlation between Fra-1 and AXL expression in bladder cancer cells. Moreover, in breast cancer cell lines, in which Fra-1 is known to be differentially expressed, its level correlated with AXL status as well (Figure 5b ). Therefore, we considered AXL to be a good candidate as a Fra-1 target, which might mediate its downstream effects on cell motility and/or proliferation. RT-PCR and western blot analysis of AXL expression in stable RT112 transfectants was consistent with the array data, confirming AXL induction by Fra-1 ( Figure 5c ). Next, we employed a negative approach to confirm the causative link between Fra-1 and AXL expression in bladder cancer cell lines. Transient depletion of Fra-1 by small interference RNA resulted in reduced AXL expression in two Fra-1-positive cell lines, J82 and UMUC-3 (Figure 5d ). The predominant Jun family member expressed in UMUC-3 and J82 cells is c-Jun (data not shown). c-Jun knockdown also reduced AXLexpression levels, thereby corroborating the role for AP-1 in AXL regulation (Figure 5d ). In agreement with the data obtained in bladder cancer cell lines, stable knockdown of Fra-1 in an unrelated colon cancer cell line, BE, resulted in loss of AXL expression (Figure 5e ). These findings suggest that AXL is a common Fra-1 target in different types of cancers. There was no AXL induction in RT112-Fra-1AA stable transfectants (Figure 5c ). This might be explained by the fact that Fra-1 expression level in these cells was insufficient to activate expression of target genes. Alternatively, phosphorylation at Ser-252 and Ser-265 might affect Fra-1 protein function independently of stabilisation. To address this issue, we transfected RT112 cells with different amounts of Fra-1AA, Fra-1DD and Fra-1 wild-type expression constructs and analysed AXL transcription in 24 h by RT-PCR. We found that if cells were transfected with higher quantities of Fra-1AA expression vector, Fra-1AA was capable of activating AXL transcription quite efficiently (Figure 6a ). In addition, we substituted Ser-252 and Ser-265 by alanines in the context of Fra-1D3. This Fra-1 derivative harbouring both, a C-terminal deletion and serine to alanine substitutions at sites 252 and 265, was expressed at very high levels in transiently transfected RT112 cells. Transient expression of either Fra-1D3 or Fra-1D3AA upregulated AXL to the same extent (Figure 6b ). These data indicate that Fra-1AA mutants retain the ability to activate expression of target genes.
Fra-1 is a direct transcriptional activator of AXL Transient expression of Fra-1 in RT112 cells was sufficient to induce AXL expression (Figure 6 ), suggesting possible Fra-1 controls motility of bladder cancer cells AE Sayan et al direct involvement of Fra-1 in AXL regulation. Analysis of AXL gene for potential TREs using the TRANSFAC programme revealed four regions containing AP-1-binding sites, in the 5 0 -flanking area (region 1), in the third intron (region 2) and in the fourth intron (regions 3 and 4) of the gene (Figure 7a ). Noteworthy, all four regions contained two or three TREs separated by 100-200 bp sequences. To analyse the in vivo interactions of these elements with Fra-1-containing complexes, we performed chromatin immunoprecipitation assays in control or RT112 cells stably expressing Fra1AA or Fra1DD mutants. Chromatin associated with Fra-1 was pulled down, and the presence of AXL gene sequences in Fra-1-enriched chromatin was assessed using primer sets spanning each of the four TRE-containing regions. Although no amplification was detected in a sample prepared from Fra-1-negative RT112 cells (CON), association between Fra-1 and regions 2, 3 and 4 was detected in cells expressing Fra1DD and to a lesser extent in Fra1AA mutants (Figure 7b ). We observed no binding of Fra-1 to the TREs located upstream of AXL gene (region 1). These data, together with the results of transient Fra-1 expression ( Figure 6 ) and RNAi ( Figures  5d and e) experiments, provide strong evidence that AXL is a direct Fra-1, target gene.
AXL stimulates cell motility but not proliferation in bladder cancer cells
Having demonstrated a direct role for Fra-1 in controlling transcription of AXL, we aimed to relate AXL with one of the Fra-1-regulated pathways. Consistent with the activation of cell proliferation in RT112 cells expressing wild-type or stabilised forms of Fra-1 Figure 6 Transient expression of wild-type or mutant Fra-1 results in AXL upregulation. RT112 cells were transfected with pIRESpuro2 empty vector or with vectors expressing wild-type Fra-1, or indicated Fra-1 mutants. Expression of AXL was analysed 24 h post-transfection by RT-PCR (a) or western blotting (b). In all western blotting experiments, an expression vector for EGFP was added to each transfection. Transfection efficiency was monitored by western blotting using an anti-EGFP antibody. Expression of HA-Fra-1 was detected with anti-HA antibody. Fra-1 controls motility of bladder cancer cells AE Sayan et al (Figure 4e ), depletion of Fra-1 in J82 (or UMUC-3, data not shown) cells strongly reduced their proliferative capacity. The effect of Fra-1 knockdown was stronger than that of c-Jun depletion. However, AXL depletion did not reduce cell growth whatsoever (Figure 8a ). On the other hand, Fra-1 or AXL depletion repressed motility of J82 cells in Transwell assay by a similar extent. Likewise, migration of another highly motile mesenchymal cell line, UMUC-3, was equally dependent on Fra-1 or AXL (Figure 8b ). We next addressed the relevance of Fra-1/AXL axis to the migration of epithelial cells in a wound-healing assay. To this end, we knocked down AXL in HT1376/Fra-1D3 cells, which, although retained their epithelial identity, acquired migratory phenotype upon Fra-1 expression. AXL depletion significantly inhibited migration of HT1376/Fra-1D3 cells into a wound, implicating this protein in epithelial cell migration (Figure 8c ). Taken together, our data show a common role for Fra-1/AXL pathway in the regulation of cell motility in mesenchymal and epithelial bladder cancer cell lines.
Discussion
Fra-1 has been reported to affect cell motility and invasion in breast, colon, thyroid and glioblastoma cancer cells (reviewed in Milde-Langosh, 2005 and Young and Colburn, 2006) . In MCF-10A cells, Fra-1 was an essential part of the EMT programme induced by activated ERK2, and EMT was prevented when Fra-1 was depleted (Shin et al., 2010) . Although stabilised Fra-1 radically changed the morphology, motility and proliferation of bladder cancer cells, these changes did not involve transcription of epithelial and mesenchymal markers and therefore could not be classified as EMT. The emerging picture indicates that although Fra-1 is essential for the maintenance of mesenchymal phenotype and is an important player in Ras-dependent EMT pathways, this protein is not a bona fide EMT inducer. Statistically reliable immunohistochemical data on Fra-1 expression have been generated in at least four forms of carcinoma, namely thyroid, oesophageal, colon and breast cancers (Chiappetta et al., 2000; Hu et al., 2001; Zhang et al., 2005; Chiappetta et al., 2007) . In the reported cases, Fra-1 expression was absent in normal epithelium and was associated either with the early (oesophageal and colon) or with late cancer stages (thyroid and breast). Characteristically for these tumour types, Fra-1 immunopositivity was observed in a very high proportion of the samples (for example, 100% of thyroid and 87% of oesophageal carcinoma samples were Fra-1-positive). In line with these observations, our data show a large (80%) proportion of muscle invasive tumours positive for Fra-1. Thus, different carcinoma (ChIP) analysis of potential Fra-1 binding sites was performed in RT112/ Fra-1AA; RT112/Fra-1DD or RT112 control cells using the anti-HA antibody. ChIP with negative IgG and anti-PolII antibodies followed by the amplification of the GAPDH promoter sequence was used as negative and positive controls, respectively, for the ChIP experiment. Total genomic DNA (20 ng) and no-DNA samples were used as PCR positive (POS) and Negative (NEG) controls. Input shows amplification of sheared DNA, not subjected to immunoprecipitation, but a proteinase K-treated and non-crosslinked sample from an equal mix of Fra-1Con, AA and DD cells.
Fra-1 controls motility of bladder cancer cells AE Sayan et al types almost inevitably acquire Fra-1 expression either at earlier or late stages of their development. This observation correlates with in vitro data showing that Fra-1 is a downstream effector of two oncogenic pathways, whose components are frequently hyperactivated in different cancer types, Wnt (Mann et al., 1999) and Ras. In superficial Ta bladder tumours, activation of Ras signalling is caused by gain-of-function mutations in HRAS, KRAS, NRAS and FGFR3. Although these mutations are less frequent in T 2 -T 4 bladder cancers, the RAS pathway seems to be affected in highstage tumours as well as by amplification/overexpression of different RTKs, including ERBB2 and ERBB1 (Knowles, 2008; Mitra and Cote, 2009) . Two levels of Fra-1 upregulation via the RAS pathway, transcriptional and protein stabilisation, have been described previously (Casalino et al., 2003; . At the transcriptional level, RAS signalling stimulates activity of a fosl1 intronic TRE sequence that interacts with Fra-1/c-Jun heterodimers in vivo and in vitro (Bergers et al., 1995; Casalino et al., 2003) . At the protein level, RAS signalling stabilises Fra-1 via phosphorylation of two C-terminal serines, Ser-252 and Ser-265, by RSK and ERK1/2, respectively, resulting in the inactivation of the C-terminal destabilising motif and escape from proteasomal degradation (Basbous et al., 2007) . Our data show that Fra-1 is phosphorylated at Ser-265 in bladder cancer cell lines and in bladder tumours. This phosphorylation stabilises the protein without affecting its ability to upregulate expression of a target gene.
We identify the AXL protein tyrosine kinase receptor as a novel Fra-1 transcriptional target. We show that (i) AXL expression correlates with Fra-1 levels in different carcinoma cell lines; (ii) it is rapidly activated by Fra-1; (iii) stable or transient Fra-1 depletion reduces AXL expression levels; (iv) intronic TREs in AXL gene are occupied by Fra-1-containing protein complexes in vivo. AXL is a member of the TAM (Tyro-3, AXL and Mer) family of receptor tyrosine kinases. AXL and its ligand, growth arrest-specific 6 are implicated in the pathogenesis of several human cancers including breast, lung, ovarian and prostate cancers and glioblastomas (Zhang et al., 2008; Shieh et al., 2005; Rankin et al., 2010; Sainaghi et al., 2005; Hutterer et al., 2008) . AXL/growth arrest-specific 6 binding results in receptor dimerisation, tyrosine phosphorylation and activation of downstream pathways that regulate cytoskeletal dynamics/cell motility, cell survival and proliferation (reviewed in Linger et al., 2008) . In addition, there is a structural basis for ligand-independent activation of AXL via homophilic cell adhesion (Heiring et al., 2004) . Indeed, AXL overexpression may lead to AXL kinase-independent cell aggregation, which then results in autophospho- Fra-1 controls motility of bladder cancer cells AE Sayan et al rylation and receptor activation (Bellosta et al., 1995; Hafizi and Dahlbaeck 2006) . Our data indicate that Fra-1-induced tumour cell motility, but not proliferation, is dependent on AXL expression levels. As Fra-1 controls tumour cell motility and proliferation and is widely expressed in cells of bladder tumours, molecular pathways upstream or downstream of Fra-1 represent attractive potential therapeutic targets. In a recent study, IHC analysis of AXL expression has been reported in T 2 -T 4 bladder cancer (n ¼ 65) (Yeh et al., 2011) . Overexpression of AXL was detected in 80% of samples, which exactly coincides with the proportion of Fra-1-positive T 2 -T 4 tumours revealed in this study. Methods of therapeutic inhibition of AXL functions have been elaborated. These methods based on the application of a blocking anti-AXL antibody (Zhang et al., 2008) , a soluble AXL ectodomain (Rankin et al., 2010) or a small-molecule inhibitor of AXL kinase (R428) (Holland et al., 2010) have demonstrated efficacy to suppress metastases in mice, and R428 inhibited breast cancer cell invasion in vitro without affecting cell proliferation. Our data suggest that the combination of targeted anti-AXL therapy with conventional antiproliferative treatments may have a potential as a new therapeutic approach in bladder cancer and in other cancer types with activated Fra-1/AXL signalling.
Materials and methods

Immunohistochemistry (IHC)
All tumour sections were obtained with ethical approval from Leicestershire, Northamptonshire & Rutland Research Ethics Committee (Reference 6433, amendment 06/Q2502/48). Paraffin sections of thickness 4 mm were deparaffinised and stained with anti-Fra-1 (Santa-Cruz Biotech, Santa Cruz, CA, USA) or anti-phospho-Fra-1 (Cell Signalling Technology, Beverly, MA, USA) antibodies. The primary antibody-antigen complexes were detected using the Novolink polymer detection system (Novocastra Laboratories Ltd, Newcastle Upon Tyne, UK). For each case a negative control was also performed using normal rabbit IgG purchased from DAKO (Glostrup, Denmark). Scoring was performed by a professional pathologist. Subcellular localisation, staining intensity and the proportion of positive cells were taken into consideration. A sample was scored as positive when immunopositivity was detected in the nuclei of more than 5% of tumour cells.
Cell culture
Cell cultures were propagated in Dulbecco's modified Eagle's medium (Life Technologies Inc, Carlsbad, CA, USA) supplemented with 10% fetal calf serum (Life Technologies Inc.) and penicillin/streptomycin (50 units/ml each). Bladder cancer cell lines were cultured in the presence of 0.1 mm non-essential amino acids.
Plasmids, RNAi, transfections and treatments We used total RNA from J82 cells to synthesise cDNA and amplify Fra-1 ORF. The ORF of wild-type Fra-1 was cloned in frame with the N-terminal HA tag in the pCGN expression vector, verified by sequencing and re-cloned in the pIRESpuro2 vector. Site-directed mutagenesis of serines and threonines corresponding to codons 219, 223, 227, 230, 240, 251, 252, 265 and 267 of Fra-1 or Leu-154 and Leu-161 (in the Fra-1LZ construct) as well as 3 0 -deletion mutants was done using conventional techniques and sequenced for validation. Short hairpin RNA targeting fosl1 sequence 5 0 -CCACCUGGUGCCAAGCAUCAA-3 0 was designed and cloned in pSM2 retroviral vector. As control, we used a nontargeting sequence in the same vector. Infection and selection for puromycin resistance colonies were carried out according to the standard protocols. Small interference RNAs targeting Fra-1 and c-Jun were described previously (Andersen et al., 2005) . Silencer-Select small interference RNA targeting AXL was obtained from Ambion, and cells were transfected by electroporation with a single pulse of 250 V and 250 Fd by using the Gene Pulser Xcell electroporation system (BioRad Laboratories, Hercules, CA, USA). To generate bladder cancer cell lines expressing Fra-1 derivatives, RT112 or HT1376 cells were transfected with either the empty vector or pIRESpuro2 containing wild-type Fra-1, or a mutant cDNA. Then, the cells were plated on 60 mm dishes and propagated in the presence of 0.5 mg/ml of puromycin for 2 weeks. After selection, Fra-1 expression was analysed in western blotting and immunofluorescence assays. Cell populations in which Fra-1 was expressed in more than 90% of the cells were selected for further experiments. For transient expression studies, cells were transfected by electroporation with pCGN-or pIRESpuro2-derived constructs. At 24 h post transfection, expression was analysed by western blotting, or cells were cultured for another 18 h in serum-free media and subjected to treatments by U0126 or EGF. Cells were treated with 10 mm U0126 for 16 h or with 50 ng/ml EGF for 2 h.
Fluorescence microscopy Cells were grown on glass microscope slides (VWR International, Fontenay-sous-Bois, France), fixed in 4% paraformaldehyde and permeabilised in 0.2% Triton X-100/PBS for 5 min. Cells were treated with Alexa Fluor 488 phalloidin, anti-HA antibody (Santa-Cruz Biotech) and secondary antibodies conjugated with Alexa Fluor 594 and DAPI. All incubations were carried out according to standard protocols.
Western blotting
Protein lysates were normalised for equal protein concentrations, denatured, separated on SDS-polyacrylamide gels and then transferred to Immobilon-P membranes (Millipore, Bedford, MA, USA) by standard procedures. After blocking with 5% w/v non-fat milk for 1 h, membranes were incubated with primary antibodies and then with appropriate horseradish peroxidise-conjugated secondary antibodies from DAKO. Signals were visualised using enhanced chemiluminescence (ECLplus, GE Healthcare, Amersham UK). Primary antibodies used in the study were anti-Fra-1 and anti-HA antibodies from Santa Cruz Biotechnology; anti-Ecadherin and anti-vimentin antibodies from BD Biosciences (Bedford, MA, USA); anti-EGFP antibody from R&D; anti a-Tubulin antibody from SigmaAldrich (St Louis, MO, USA); and anti-phospho-Fra-1 antibody was either home-made (Basbous et al., 2007) or obtained from Cell Signalling Technology.
In vitro dephosphorylation reaction Proteins were extracted from J82 cells in Triton lysis buffer (20 mm Tris (pH 8.0), 120 mm NaCl, 10% glycerol, 1 mm EDTA, 0.5% Triton X-100 and 0.5 mm phenylmethylsulphonyl fluoride) and incubated with or without 20 U calf intestinal phosphatase in the presence or absence of 10 mm sodium orthovanadate for 1 h at 4 or 37 1C. After the reaction was completed, samples were analysed by western blotting.
RT-PCR analysis
In all, 1 mg of total RNA extracted by the TRIZOL reagent (Life Technologies Inc.) was used in reverse transcription reaction. The reactions were carried out for 40 min at 50 1C using Superscript III reverse transcriptase (Life Technologies Inc.) and random hexamer primer mixture (GE Healthcare). Products were amplified in PCR reactions using 2.5 units Taq DNA polymerase (Sigma-Aldrich). Amplicons were from coding parts of genes, and primers in each pair were designed to correspond to different exons.
Gene expression analysis
Total RNA (2 mg) isolated from RT112/control and RT112/ Fra1DD cells were reverse transcribed using the High Capacity RT kit (Life Technologies Inc.) with random hexamer primers followed by ExoI (GE Healthcare) treatment at 37 1C for 1 h. qPCR was performed using the OpenArray system. The OpenArray technology is based on a metal plate containing self-metered 33 nanoliter through-holes loaded with primer pairs (Dixon et al., 2009) . PCR assay performance in the nanoplates is equivalent to the same assay in microplates, but with over 150-fold lower reaction volume (33 nl versus 5 ml reaction volumes). Two cDNA samples in duplicates at the concentration of 100 ng/ml were mixed with qPCR reagents for SYBR Green qPCR (Fast Start DNA SYBR Green kit, Roche, Mannheim, Germany) and profiled on Cancer Pathways OpenArray containing 625 pre-validated real-time qPCR assays. The Cancer Pathways OpenArray plate includes primer pairs specific for genes associated with cell motility, adhesion, angiogenesis, cell cycle and apoptosis. Real-time PCR occurred in a computer-controlled imaging thermal cycler (Life Technologies Inc.). Post-acquisition data processing generated fluorescence amplification and melt curves for each through-hole in the array, from which melt temperature (T m ) and cycle threshold (C T ) were computed and used for DDC T calculation.
Chromatin immunoprecipitation
Chromatin purification and precipitation was done using the Active Motif kit (Active Motif, Rixensart, Belgium) following the manufacturer's instructions and using HA-7 antibody (Sigma -Aldrich). For each chromatin preparation, cells grown in a 70% confluent 15-cm plate were fixed with 1% formalin for 5 min at room temperature. Fixation was stopped by washing with ice-cold PBS and incubating the cells with an excess of glycine, after which cells were harvested and pelleted. Nuclei from collected cells were extracted using a Dounce homogeniser and precipitated by brief centrifugation (2400 RCF for 5 min). Chromatin was sheared using sonication with one quarter setting (25 s for four times on ice). One tenth of sheared chromatin was used for each precipitation or input control (no precipitation, only reverse cross-linking and Proteinase-K treatment). Chromatin immunoprecipitation was performed using HA-7 antibody (overnight at 4 1C) and protein G magnetic beads. After extensive washing of chromatin-protein G complex, the samples were eluted, reverse cross-linked and treated with Proteinase-K. Following the inactivation of Proteinase-K, the sample was used for PCR amplifications as a source of Fra-1 responsive promoterenriched genomic DNA.
Cell proliferation assay Cells were seeded (500 cells/well) in triplicate in a 24-well plate. At 24, 48, 72 and 96 h after seeding, one set of triplicate was fixed with 50/50% acetone/methanol and stained with DAPI. Then, the picture of each well was taken using UV filter to image nuclei of cells with the Â 4 objective. After all the pictures were acquired, cell nuclei in each well were counted using Image-J software (NIH; http://rsb.info.nih.gov/ij/).
Cell motility assays
Transwell migration assays (for J82, UMUC3 and RT112 cells) were performed by seeding 2 Â 10 5 cells in 8 m pore size BD-Falcon 24 Transwell inserts. Two hours after seeding, the media at the top component was aspirated and replaced with serum-free media for creating a chemo-attractant gradient and then allowed to migrate for 4 or 6 h. Then, the cells on both sides of the chamber were fixed with 50/50% acetone/methanol. The cells on the top compartment were stained with 1% aqueous eosin and wiped with a cotton bud swipe and the cells at the bottom of the chamber were stained with DAPI. The number of cells on the bottom compartment was determined as described in cell proliferation assay. Scratch-wound-healing assays were carried out using time-lapse microscopy by taking one picture in every 15 min. Briefly, RT112 and HT1376 cells were seeded at high density to six-well plates (6-7.5 Â 10 5 cells/well). After the monolayer was formed, a scratch was inflicted using a white tip. The detached cells were washed away with PBS and the cells at the scratch were imaged at multiple locations from the same well and replica wells. Images of cell migration were captured for up to 66 h. The closure of scratch was measured by analysing images at specific time intervals by Image-J programme.
